PLAC1 is widely expressed in head and neck cancers and a peptide epitope derived from it can stimulate helper T cells to kill PLAC1-positive tumor cells.
74.5%Of oropharyngeal tumors express PLAC1, making it a widely applicable target
What the researchers found
A PLAC1-derived peptide epitope (PLAC131-50) stimulates promiscuous helper T cell responses that kill PLAC1-positive HNSCC cells in an HLA-DR-restricted manner, with reactive T cells detected in patient blood.
Why it matters
Identifying a promiscuous peptide epitope that works across multiple HLA types means PLAC1-based immunotherapy could benefit a broader patient population.
The numbers in context
74.5% oropharyngeal, 51.9% oral tumors express PLAC1; PLAC131-50 promiscuous across HLA-DR; patient blood T cells reactive
How the study worked
Tumor tissue immunohistochemistry for PLAC1 expression, peptide binding assays, T cell stimulation assays, and cytotoxicity assays against HNSCC cell lines.
Who was studied
HNSCC patient tumor samples and blood; HNSCC cell lines
What this study cannot tell us
Preclinical study without in vivo validation. T cell responses were measured in vitro and may not reflect therapeutic efficacy in patients.
How to read the evidence
Preclinical immunology study demonstrating in vitro proof-of-concept. Strong mechanistic data but no clinical validation yet.
When this study was published
Published in 2020. The peptide epitope discovery remains relevant as cancer vaccine development continues to advance.
The bigger picture
This work adds PLAC1 to the growing list of cancer-testis antigens that could be targeted by peptide vaccines, potentially expanding treatment options for head and neck cancer patients.
Questions still open
- Could a PLAC1-based peptide vaccine be combined with checkpoint inhibitors for enhanced anti-tumor responses?
- Does PLAC1 expression vary by HPV status in oropharyngeal cancers?
- Would combining CD4 and CD8 epitopes from PLAC1 produce stronger anti-tumor immunity?
Common questions
What is PLAC1 and why is it a good cancer target?
How does a peptide vaccine work against cancer?
Read the original research
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Oncoimmunology, 10(1), 1856545
Citation
Hayashi, Ryusuke; Nagato, Toshihiro; Kumai, Takumi; Ohara, Kenzo; Ohara, Mizuho; Ohkuri, Takayuki; Hirata-Nozaki, Yui; Harabuchi, Shohei; Kosaka, Akemi; Nagata, Marino; Yajima, Yuki; Yasuda, Syunsuke; Oikawa, Kensuke; Kono, Michihisa; Kishibe, Kan; Takahara, Miki; Katada, Akihiro; Hayashi, Tatsuya; Celis, Esteban; Harabuchi, Yasuaki; Kobayashi, Hiroya. (2020). Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.. Oncoimmunology, 10(1), 1856545. https://doi.org/10.1080/2162402X.2020.1856545